ephedrine + pioglitazone

Ephedrine + pioglitazone is a hypothetical or non-standard combination of two small molecule drugs with distinct mechanisms and indications. Ephedrine is a sympathomimetic amine that acts as an agonist at adrenergic receptors, increasing the release of norepinephrine and stimulating both alpha- and beta-adrenergic receptors. It is primarily used for temporary relief of bronchial asthma symptoms, low blood pressure, and as a decongestant[5]. Pioglitazone is a thiazolidinedione-class antidiabetic agent that acts as an agonist at peroxisome proliferator-activated receptor gamma (PPARγ), improving insulin sensitivity in peripheral tissues; it is indicated for glycemic control in type 2 diabetes mellitus[1]. There are no known approved pharmaceutical products combining these two agents, nor evidence supporting their combined use in clinical practice. Notably, co-administration may result in pharmacodynamic antagonism or increased risk due to opposing effects on glucose metabolism and cardiovascular stimulation.

Other names

ephedrine + pioglitazone